At the Medicap Pharmacy® stores, we are dedicated to providing products and services to care for your family’s wellness. One of those services is health news you can trust. Use the filters to focus on the information that is important to you, then bookmark this page to make it a regular stop anytime you’re online.
Rx Combo Slowed Multiple Myeloma
When it comes to treating multiple myeloma, three medications may be better than two.
Blood Cancer Rx Trial Halted
The purpose of clinical trials is to study the safety and effectiveness of a medication. Sometimes, clinical trials involving humans find that a medication does not work and the study is stopped. This just happened in a trial looking at a blood cancer medication.
FDA Approves Lenalidomide
On June 5, 2013, the US Food and Drug Administration approved lenalidomide capsules (REVLIMID, Celgene Corporation), for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
Personalizing Blood Cancer Treatment
Huge advances have been made in the understanding of multiple myeloma. There are a variety of approaches for treating this blood cancer. The trick is to provide what’s best for the individual patient.
Closing In on a Cure
Someone diagnosed with any type of leukemia in the early 1960s had about a 14 percent chance of being alive five years later. Today, those chances are vastly greater.
New Rx for Advanced Multiple Myeloma
Multiple myeloma is a blood cancer that affects nearly 22,000 Americans every year. It develops in mostly older people when plasma cells in the bone marrow grow out of control.
Stronger Blood Cancer Drug Appears Successful
Part of the treatment for especially severe cancers of the blood is to destroy all the cells in the bone marrow that are responsible for making both the good and bad parts of the blood with radiation therapy.
Revlimid and Risk of New Cancers
The U.S. Food and Drug Administration (FDA) is informing the public of an increased risk of second primary malignancies (new types of cancer) in patients with newly-diagnosed multiple myeloma who received Revlimid ( lenalidomide ).
Cancer Rx Linked to Second Cancers
Health Canada, the Canadian version of the U.S. Food & Drug Administration (FDA), has issued an alert regarding the medication REVLIMID ( lenalidomide ) that's used to treat multiple myeloma .
Keys to Unlocking Multiple Myeloma Resistance
People living with the blood cancer multiple myeloma typically take two drugs in combination. The problem is these drugs don't work with every person and tend to fade in effectiveness over time.